Loring Wolcott & Coolidge Fiduciary Advisors LLP Editas Medicine, Inc. Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$11.1 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $769 - $1,176	-29 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $907 - $1,642	29 New	29 $2,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

Black Rock Inc. New York, NY

7.78M
Shares

$10.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$8.75 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.9M
Shares

$6.42 Million
0.62% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.35M
Shares

$4.39 Million
0.01% of portfolio
State Street Corp Boston, MA

2.46M
Shares

$3.23 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account